Background: It is claimed that breast cancer is the most common and devastating disease. Different anticancer drugs are used to treat different types of tumors with drug categories affecting abnormal cells in many ways. For adjuvant treatment, researchers have shown that certain chemotherapy drug combinations are sometimes more effective than single drug treatment. To treat a breast tumour, chemotherapy drugs or their combinations may be given as adjuvant therapies such as doxorubicin plus cyclophosphamide (AC) and docetaxel plus cyclophosphamide (TC) which is the focus of this research. Aim and Objectives: The aim of the study is to determine the better drug combination either Docetaxel or Doxorubicin in combination with Cyclophosphamide in patients with breast cancer. The objective of the study is compare the outcomes of the Chemotherapeutic drug combinations in terms of Disease-free Survival and Overall Survival rates. Methodology: It is a Retrospective Comparative study between the Two adjuvant chemotherapy drug combinations used in Breast Cancer Treatment i.e., Docetaxel with Cyclophosphamide vs Doxorubicin with Cyclophosphamide. The Patients data were collected based upon the Inclusion and Exclusion Criteria. Then they were randomly allocated into two groups by random sampling technique. One group (Group A) received Standard Adjuvant Chemotherapy Regimen Doxorubicin and Cyclophosphamide (AC), Whereas another group (Group B) received Docetaxel and Cyclophosphamide (AT) for 3 to 4 cycles depending on the Patient condition, data were collected and compared in terms of Primary end points on Disease Free Survival (DFS), Overall Survival (OS), and relapse rate to find out the better adjuvant chemotherapeutic regimen in the treatment of Breast Cancer. The Standard Dose of two drug combinations administered to the Groups A and B are Group A: 1. Doxorubicin 60mg and 2. Cyclophosphamide 600mg/m2 , whereas Group B received 1. Docetaxel 75mg and 2. Cyclophosphamide 600mg/m2 Conclusion: This retrospective study compared the Adjuvant TC regimen (Docetaxel with Cyclophosphamide) with the sequential regular Classical regimen of AC (Doxorubicin with Cyclophosphamide) in terms of the Progression Free Survival and Disease-free Survival. It is found that as far as Progression Free Survival is considered, there are no significant differences between the Both AC and TC regimen, But When Overall Survival is concerned, the TC Regimen is better drug Combination in treating the Breast Cancer. Both Treatment Regimens (TC & AC) was well tolerated with respect to Prognostic Factors, but as far as Adverse Effects and overall survival is considered, TC Regimen (Docetaxel and Cyclophosphamide) is better tolerated and can be recommended Adjuvant Cancer chemotherapeutic regimen in Breast Cancer Patients